

ABOS · NASDAQ · WEEK ENDED 24 JUL 2026

Weekly Investor Report

Acumen Pharmaceuticals Inc · Healthcare · Biotechnology

LATEST CLOSE

2.13 USD

-5.3% latest week

Weekly setup

Weak trend

The weekly trend is not active. Price is -13.9% below the Trend Line and sits at 39.0% of its 52-week range. The latest completed week returned -5.3%, after a -9.7% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 44/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 12d.

Technical setup score 25/100. This score describes the weekly technical setup; the conclusion above also considers fundamentals, positioning, sentiment, and event risk.

LATEST CLOSE

2.13 USD

24 Jul 2026

1W RETURN

-5.3%

latest completed week

4W RETURN

-9.7%

short-term follow-through

12W RETURN

-10.5%

quarterly tape

TREND BREADTH

80.8%

42 of 52 weeks active

VOLUME RATIO

0.5x

vs 13-week average

What is working

- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.

What could go wrong

- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.

What to watch next

- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.

This week's evidence at a glance

PRICE FOLLOW-THROUGH

-5.3%

Latest completed week; four-week move -9.7%.

INDICATOR STACK

44/45

Trend and activity pressure are weighted against the latest 12-week confirmation window.

TREND BACKDROP

Active

The trend backdrop defines the current weekly regime.

PATIENT CAPITAL

Quiet

Activity-pressure buy-signal status for institutional accumulation timing.

NEXT-WEEK EXPECTANCY

Negative 43.87%

Historical one-week expectancy contributes to the evidence score when direction is confirmed.

OPTIONS PRESSURE

Bullish

44/100 conviction; expected move 39.4%.

NEWS SENTIMENT

55/100

54 relevant articles in the latest sentiment read.

EVENT RISK

12d


Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.

01 · PRICE ACTION

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -13.9% below the Trend Line and sits at 39.0% of its 52-week range. The latest completed week returned -5.3%, after a -9.7% four-week move.

52-week price path



Blue: weekly close · Green: Trend Line · Orange: Sharemaestro Fair Value

Position in the 52-week range



1.19 USD

3.60 USD

Latest close sits at 39.0% of the 52-week range.

RANGE LOCATION

39.0%

Shows where the latest close sits between the 52-week low and high.

TREND DISTANCE

-13.9%

Price premium or discount versus the weekly Trend Line.

FAIR-VALUE GAP

-16.6%

Premium demand or model discount versus Sharemaestro Fair Value.

HIGH-WATER GAP

-40.8%

Distance from the latest 52-week high.


02 · VOLUME AND DEMAND

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows weekly volume. Green marks an up week; orange marks a down week.



PARTICIPATION 0.5x Latest volume versus the 13-week average.	BASELINE 2.1M 13-week average volume.	ONE-YEAR BASE 2.2M 52-week average volume.	LATEST WEEKLY VOLUME 1.1M Most recent completed week.
---	--	---	--

Demand beneath price

Activity pressure and institutional-style signals


These indicators assess whether participation is improving beneath price. They are supporting evidence, not proof of institutional buying.



03 · MOMENTUM AND LEADERSHIP

Is performance persistent—and is the stock leading?

Performance is -9.7% over four weeks, -10.5% over 12 weeks, and 35.7% over one year. The current trend has remained active for 0 consecutive weeks.



Technical setup scorecard

Trend		44
Momentum		18
Activity Pressure		45
Relative Leadership		0
Next-Week Expectancy		28
Volume		22
Smart Money		43
Risk Control		0

04 · FUNDAMENTALS AND VALUATION

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

FACTOR WEEK 26 Jul 2026 Latest published factor snapshot.	STATEMENTS THROUGH 31 Dec 2025 Financial reporting period used.	FIELD COVERAGE 67% Available factor fields.	MODEL CONFIDENCE 64% Snapshot confidence.
--	--	--	--

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength		75/100
Value		62/100
Quality		60/100
Momentum		62/100
Growth		62/100

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E Price divided by trailing earnings.	-
PRICE / SALES Market value relative to trailing revenue.	-
EV / EBITDA Enterprise value relative to operating cash earnings.	-
FREE-CASH-FLOW YIELD Free cash flow as a share of enterprise value.	-79.2%

Business quality

Margins and the return generated on invested capital.

GROSS MARGIN Gross profit retained from each unit of revenue.	-
OPERATING MARGIN Operating profit retained from revenue.	-
FREE-CASH-FLOW MARGIN Free cash flow generated from revenue.	-
RETURN ON INVESTED CAPITAL Operating return generated on invested capital.	-122.3%

04 · FUNDAMENTALS AND VALUATION · CONTINUED

Growth, shareholder returns, and balance-sheet strength

The second half of the fundamental read separates recent business growth from cash returned to shareholders and financial leverage.

Growth and financial strength	Shareholder return and balance sheet
Recent business growth and accounting strength.	Cash returned to owners and financial leverage.
REVENUE GROWTH -	DIVIDEND YIELD -
Latest one-year revenue growth.	Cash dividends relative to market value.
EPS GROWTH -	BUYBACK YIELD -23.1%
Latest one-year earnings-per-share growth.	Net share repurchases relative to market value.
FREE-CASH-FLOW GROWTH -	SHAREHOLDER YIELD -23.1%
Latest one-year free-cash-flow growth.	Dividend yield plus net buyback yield.
PIOTROSKI F-SCORE 1/9	NET DEBT / EBITDA 0.2x
Nine-point accounting-strength checklist.	Balance-sheet debt relative to operating cash earnings.

How to read this


Quality and valuation are separate questions. A strong company can still carry a demanding valuation, so profitability, growth, balance-sheet strength, and the price paid for those characteristics should be assessed independently.

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

05 · OWNERSHIP, OPTIONS, AND SENTIMENT

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.



06 · CATALYSTS AND RISK

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly gains and losses frame the risk around the current setup.

NEXT EARNINGS
12d
Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.


OPTIONS EXPECTED MOVE
39.4%
Nearest-chain priced movement where available.

52-WEEK DRAWDOWN
-40.8%
Distance below the 52-week high.

13-WEEK VOLATILITY
10.0%
Standard deviation of weekly returns.

Weekly gains and losses

Each bar is one completed week. Gains rise above zero; losses fall below it. Taller bars mean a larger move.



WEEKS HIGHER
13 of 26
13 weeks finished lower.

BEST WEEK
+31.3%
Week of 30 Jan.

WORST WEEK
-18.3%
Week of 20 Mar.

LATEST WEEK
-5.3%
Week of 24 Jul.

Shape of recent returns

Strong gains		11
Modest gains		2
Flat weeks		-
Modest losses		1
Sharp losses		12

RECENT VOL
10.0%
13-week weekly-return volatility.

BASE VOL
11.7%
52-week weekly-return volatility.

UP/DOWN SPLIT
26/25
Count of positive and negative weeks in the 52-week window.

AVERAGE SKEW
10.8% / -8.7%
Average positive week versus average negative week.

07 · SECTOR AND PEER CONTEXT

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

Sector · US Healthcare

4-WEEK RANK - / 100 Standing within the tracked group.	GROUP AVERAGE 1.3% Average four-week return.	TREND BREADTH 51.0% Share of peers with an active trend.
---	---	---

Peer	Exchange	1W return	4W return	Trend
ABVX	NASDAQ	-8.0%	28.9%	Active
THC	NYSE	19.6%	23.4%	Inactive
BBIO	NASDAQ	3.2%	19.6%	Active
ONC	NASDAQ	4.4%	16.4%	Inactive
MEDP	NASDAQ	11.8%	14.1%	Inactive

Industry · US Biotechnology

4-WEEK RANK - / 100 Standing within the tracked group.	GROUP AVERAGE 0.5% Average four-week return.	TREND BREADTH 67.0% Share of peers with an active trend.
---	---	---

Peer	Exchange	1W return	4W return	Trend
CRNX	NASDAQ	-0.2%	128.1%	Active
ABVX	NASDAQ	-8.0%	28.9%	Active
BBIO	NASDAQ	3.2%	19.6%	Active
ERAS	NASDAQ	-0.3%	19.4%	Active
IOVA	NASDAQ	-0.2%	17.4%	Active

08 · EVIDENCE AND WEEKLY DATA

The underlying research record

Every top-level statement should be traceable to a stored market, fundamental, event, or positioning observation.

Cross-signal evidence matrix

Evidence pillar	Score / read	Summary	Detail
Weekly tape	28/100	Trend, activity pressure, participation, and risk combine to a 28/100 tape read.	
Indicator analysis	34/100	Latest 12-week confirmation: trend 5/12, activity pressure 0/12, relative leadership 6/12.	Activity pressure 0.32; No reversal markers
Next-Week Expectancy	Negative 43.87%	Next-week expectancy is negative with a 43.87% historical one-week setup read.	Adds short-term historical context without overriding trend, activity, or relative leadership.
Factors	64/100	O'Shaughnessy factor stack blends value, quality, momentum, and confidence.	Buyback Yield rank 92; Small Cap Core rank 46
Patient Capital	Quiet	Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.	No recent buy signal
Options	52/100	ABOS shows bullish options pressure with a 44/100 conviction score, put-call volume ratio of 0.53, expected move of 39.4%, and Sharemaestro trend signal inactive.	Bullish · Call-side pressure · Expected move 39.4%
Sentiment	55/100	Weighted news tone is neutral across 54 relevant articles.	Enterprise value to revenue forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS
Insiders	14 / 6	14 acquisitions and 6 disposals in the latest 180-day insider tape.	
Earnings	12d	Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.	

Current evidence clusters

PRICE FOLLOW-THROUGH -5.3% Latest completed week; four-week move -9.7%.	INDICATOR STACK 44/45 Trend and activity pressure are weighted against the latest 12-week confirmation window.	TREND BACKDROP Active The trend backdrop defines the current weekly regime.	PATIENT CAPITAL Quiet Activity-pressure buy-signal status for institutional accumulation timing.
NEXT-WEEK EXPECTANCY Negative 43.87% Historical one-week expectancy contributes to the evidence score when direction is confirmed.	OPTIONS PRESSURE Bullish 44/100 conviction; expected move 39.4%.	NEWS SENTIMENT 55/100 54 relevant articles in the latest sentiment read.	EVENT RISK 12d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.

Recent completed weeks

The completed weekly bars behind the report provide a compact audit trail for price, trend, Fair Value, activity pressure, leadership, and volume.

Week	Close	Return	Trend Line	Fair Value	Pressure	Leadership	Volume	Trend
24 Jul 2026	2.13 USD	-5.3%	2.47 USD	2.55 USD	-0.47	-9.18	1.1M	Off
17 Jul 2026	2.25 USD	-14.4%	2.47 USD	2.59 USD	-0.26	-5.42	2.6M	Off
10 Jul 2026	2.63 USD	-4.0%	2.47 USD	2.62 USD	-0.39	6.29	1.5M	Off
03 Jul 2026	2.74 USD	16.1%	2.45 USD	2.64 USD	-0.59	13.44	2.2M	Off
26 Jun 2026	2.36 USD	4.4%	2.42 USD	2.66 USD	-0.93	-0.47	7.2M	Off
19 Jun 2026	2.26 USD	-4.6%	2.41 USD	2.68 USD	-1.00	-8.29	2.3M	Off
12 Jun 2026	2.37 USD	10.2%	2.38 USD	2.70 USD	-0.89	-0.82	1.6M	Off
05 Jun 2026	2.15 USD	-17.3%	2.36 USD	2.72 USD	-0.86	-7.28	1.6M	On
29 May 2026	2.60 USD	3.6%	2.35 USD	2.74 USD	-0.76	7.57	1.0M	On
22 May 2026	2.51 USD	10.1%	2.34 USD	2.75 USD	-0.78	7.83	2.1M	On
15 May 2026	2.28 USD	-10.9%	2.33 USD	2.77 USD	-0.70	0.02	1.5M	On
08 May 2026	2.56 USD	7.6%	2.32 USD	2.79 USD	-0.44	12.72	1.3M	On
01 May 2026	2.38 USD	-7.4%	2.31 USD	2.81 USD	-0.29	11.62	1.3M	On
24 Apr 2026	2.57 USD	-8.9%	2.29 USD	2.83 USD	-0.05	23.38	1.7M	On

How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown in the fundamentals section.

Educational market research only. Not financial, investment, trading, tax, or legal advice. Market data, indicators, summaries, and reports may be delayed, incomplete, or inaccurate. You are responsible for your own decisions and should seek independent professional advice where appropriate.

Open the live report · Open the interactive chart · Full disclaimer